Aikido Pharma Inc AIKI:NASDAQ

Set AlertOptionsStreaming Charts
Last Price$6.15NASDAQ Previous Close - Last Trade as of 3:59PM ET 8/12/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$6.15 (6)
Ask (Size)$6.24 (2)
Day Low / HighN/A - N/A
Volume31.6 K
Sell
Buy
Chart Style Historical Chart Icon Download historical data
 

View Biotechnology IndustryPeer Comparison as of 08/12/2022

Timeframe
 

Aikido Pharma Inc ( NASDAQ )

Price: $6.15
Change: +0.05 (0.82%)
Volume: 31.6 K
3:59PM ET 8/12/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

VistaGen Therapeutics Inc ( NASDAQ )

Price: $0.16
Change: -0.02 (10.06%)
Volume: 20.7 M
4:00PM ET 8/12/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Marker Therapeutics Inc ( NASDAQ )

Price: $0.39
Change: -0.05 (12.24%)
Volume: 979.4 K
4:00PM ET 8/12/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Caladrius Biosciences Inc ( NASDAQ )

Price: $0.54
Change: +0.007 (1.34%)
Volume: 94.9 K
3:57PM ET 8/12/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

T2 Biosystems Inc ( NASDAQ )

Price: $0.19
Change: -0.007 (3.36%)
Volume: 139.3 M
4:00PM ET 8/12/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain

Read more news Recent News

AIkido Pharma Confirms Unsolicited Offer From Shalom Auerbach to Buy Its Shares for $8 Per Share
9:23AM ET 8/10/2022 MT Newswires

AIkido Pharma (AIKI) confirmed Wednesday it has received an unsolicited offer from Shalom Auerbach to buy all of its outstanding shares for $8 per share in...

AIkido Pharma Activist Investor Shalom Auerbach Submits Cash Buyout Proposal at $8 a Share
11:18AM ET 8/09/2022 MT Newswires

AIkido Pharma (AIKI) activist investor Shalom Auerbach said Tuesday he has sent a letter proposing to acquire the remaining stake in the biotechnology...

AIkido Pharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement
11:41AM ET 6/28/2022 MT Newswires

AIkido Pharma (AIKI) said Tuesday it has been notified that it has regained compliance with Nasdaq's $1 minimum bid price requirement for continued...

AIkido Pharma Forms Financial Services Unit
9:41AM ET 6/24/2022 MT Newswires

AIkido Pharma (AIKI) said Friday it has set up a financial services unit to invest and make acquisitions in the financial technology and financial services...

View all Commentary and Analysis

AIkido Pharma: Advancing Anticancer And Antiviral Therapies
12:26PM ET 2/10/2022 Seeking Alpha

Company Profile

Business DescriptionAIkido Pharma, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. Its oncology therapeutics includes treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It also creates broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. The company was founded by Gilbert V. Levin and M. Karen Levin in 1967 and is headquartered in New York, NY. View company web site for more details
AddressOne Rockefeller Plaza
New York, New York 10020
Phone+1.12.745.1374
Number of Employees6
Recent SEC Filing08/12/202210-Q
Director, Chief Executive & Financial OfficerAnthony C. Hayes
Vice President-Drug Development & General CounselDarrell Dotson

Company Highlights

Price Open$6.16
Previous Close$6.10
52 Week Range$4.30 - 16.58
Market Capitalization$32.3 M
Shares Outstanding5.3 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/10/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.33
Beta vs. S&P 500N/A
Revenue$28.0 K
Net Profit MarginN/A
Return on Equity-6.35%

Analyst Ratings as of 04/06/2022

Buy
1
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset